FORT LAUDERDALE, Fla., Jan. 30 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., , a pioneer in laser optical breast imaging systems, announced the issuance of U.S. Patent 7,155,274, entitled “Optical Computed Tomography Scanner for Small Laboratory Animals,” its 17th US patent in the optical CT field.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO)
“This patent covers the key claims of our Laser Imager for Laboratory Animals (LILA), and is the cornerstone of the intellectual property being exclusively licensed to Bioscan, Inc., a Washington, DC, company that intends to commercialize the technology. Specifically, this patent protects the concepts of a helical optical CT scanner optimized for simultaneously imaging attenuation and fluorescence in small laboratory animals,” stated Robert Wake, IDSI’s VP of Engineering.
IDSI also noted that, since a previous release on US patents issued in 2004, 9 international patents have issued to IDSI, more than doubling IDSI’s international patent portfolio to 15 and its total portfolio to 32 patents. “Our main business is human breast optical imaging with CTLM systems, where we command a leadership position, as evidenced by our global portfolio,” commented Wake.
Recent international patents include:
Australian patent 775069, issued July 2004; European patent EP01181511, issued June 2005; Hong Kong patent HK1043480, issued January 2006; and German patent DE69925869 issued May 2006; all entitled “Laser Imaging Apparatus Using Biomedical Markers That Bind to Cancer Cells.” These 4 patents, along with a previously issued Canadian patent, are equivalents of US patent 5,952,644 and protect the concept of imaging and activating a photodynamic therapy agent in an optical CT scanner, a combined diagnostic and therapeutic system.
European patent EP01005286, issued July 2004, and Hong Kong patent HK1029508, issued December 2004, both entitled “Method for Reconstructing the Image of an Object Scanned with a Laser Imaging Apparatus,” are equivalents of US patent 6,130,958. These 2 patents protect the image reconstruction algorithms employed in CTLM technologies.
Hong Kong patent HK1029506, issued December 2004, entitled “Device for Determining the Contour of the Surface of an Object Being Scanned,” is equivalent to US patent 6,044,288. It, along with a previously issued European patent, protects the perimeter-measurement technique employed in the CTLM, which is essential to reconstructing optical CT images.
Chinese patent ZL01809326.4, entitled “Multiple Wavelength Simultaneous Data Acquisition Device for Breast Imaging,” issued in November 2005. This patent, equivalent to US patent 6,571,116, protects the concept of multiple wavelength optical data acquisition in an optical CT scanner for the purpose of tissue characterization.
European patent EP01389441, issued May 2006, entitled “Diagnostic Tomographic Laser Imaging Apparatus.” This patent, equivalent to US patent 5,692,511, protects the basic CTLM optical CT concept.
The CTLM(R) system is a new continuous wave laser breast imaging system that utilizes state-of-the-art technology and patented algorithms to create 3- D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to radiation or require breast compression. In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.
CONTACT: Investor Relations: Rick Lutz, +1-404-261-1196,lcgroup@mindspring.com, for Imaging Diagnostic Systems, Inc.
Web site: http://www.imds.com//